Abstract. The blanching activities and hence bioavailabilities of the cream, ointment and fatty ointment preparations of Nerisone@ and Temetex@ (diflucortolone valerate 0.1%) were evaluated using an occluded and unoccluded blanching assay. These products were compared to Synalar@ ointment and cream (fluocinolone acetonide 0.025%), established topical corticosteroid preparations. Statistical analysis showed no significant differencesbetween similar formulations of diflucortolone valerate. Significant differences were noted between diflucortolone valerate and fluocinolone acetonide preparations.
Temetex and Nerisone are both available as cream, ointment and fatty ointment formulations containing 0.1% diflucortolone valerate. It is a wellestablished fact that the nature of the base affects both the rate of release of the active ingredient and the therapeutic effect in topical corticosteroid therapy, e.g., cream bases have a low fat and high water content making them suitable for acute and weeping conditions. Although both Nerisone and Temetex contain the same corticosteroid in the same concentration, it has previously been shown [2, 3] that this does not necessarily imply bioequivalence of the active ingredient.
The aim of the present study was, therefore, to compare the blanching activities of the different formulations to ascertain whether there is any difference in the rate of release of diflucortolone valerate from the same type of base compounded by different manufacturers, and also to compare the rates of release of the steroid from the three different types of base. Ointment and cream formulations of iluocinolone acetonide were included in order that a comparative potency could be ascribed to the diiluocortolone valerate preparations.
Materials and Method
Tubes of Nerisone fatty ointment, ointment and cream (prepared in Germany), Temetex fatty ointment, ointment and cream (prepared in Switzerland) and Synalar ointment and cream (prepared in South Africa) were purchased from a local pharmacy.
Two trials were performed using a modified McKenzie-Stoughton blanching assay [11.In the first trial the blanching activities of Nerisone ointment and fatty ointment were compared with those produced by Temetex ointment and fatty ointment. The degree of blanching produced by Synalar ointment was also monitored. In the second trial Nerisone cream was compared with Temetex cream. Also included were Synalar cream and Nerisone ointment. The inclusion of the latter formulation allowed for intercomparison between the two trials. 10 human volunteers were used per trial. The flexor aspects of the forearms were masked producing 12 7 mm square application sites per arm. A standard mass (approximately 4 mg) of each preparation was applied to the application sites in a random manner. For each volunteer both arms were used, one set of applications being occluded using a non-porous plastic film, the other being left unoccluded but protected with a cardboard frame in order to prevent spreading. 6 h after application the maskings and frames were removed and the forearms washed with soap and warm water. The arms were evaluated independently using a double-blind technique by three observers at various time intervals adequate to establish a blanching profile. The averaged readings of all observers were used to analyse the data.
The results were statistically analysed using three methods.
(a) Number of sites exhibiting blanching. This method involved a yes/no determination of whether or not blanching was evident at each application site.
(b) Intensity of blanching. A visual determination of the degree of blanching produced at each site was made by this method. A response scale was defined as follows: O=no blanching; 1 = faint pallor, clear outline of application site not visible; 2=moderate blanching, square outline of application site clearly visible; 3 = intense blanching over the whole application site.
The percent total possible score (% TPS) was calculated using the following method. The maximum score per site is equal to 3. For 10 volunteers each having z sites per arm and three independent observers, TPS=3 x 10xzx3, actual score %TPS= x 100. TPS (c) Paired comparison of adjacent application sites. This method involved the direct comparison of different formulations applied as pairs. For each pair the following decision was required. One site exhibited a greater degree of blanching, both sites showed equal blanching or blanching was not observed at either site.
The data obtained from (a) and (c) were analysed by X' techniques. A 2x2contingency table was examined employing Yates' correction factor for continuity for results from (a), whereas the X' procedure of McNemar was used for results from (c). The data obtained from (b) were tabulated for each product and application mode. Since a four point intensity score was used, a 2 x 4 contingency table was obtained for each of the product comparisons. Three degrees of freedom were assumed.
Area under the curve (AVe) measurements were also utilized.
Results and Discussion
Figures 1 and 2 depict the blanching profiles obtained for both the ointment and fatty ointment preparations in the occluded and unoccluded modes, respectively. Figures 3 and 4 depict the blanching profiles obtained for the cream formulations (including Nerisone ointment) in the occluded and unoccluded modes, respectively. Table I lists the blanching responses for each formulation. x2 analysis showed significant differences in favour of both Nerisone and Temetex ointments relative to Synalar ointment from the 7-to l8-hour range in both the occluded and unoccluded modes. From 18 to 28 h after application, lluocinolone acetonide displays its longer acting effect. There are few statistically significant differences between the ointment and fatty ointment formulations in either the occluded or un occluded application mode. There are no statistically significant differences between Nerisone and Temetex ointments or between Nerisone and Temetex fatty ointments in either mode of application.
The blanching profiles indicate that dillucortolone valerate shows a more rapid rate of release from the vehicle associated with a higher degree of blanching and a more rapid removal from the site of action when compared to lluocinolone acetonide in both cream and ointment formulations. The rapidity of onset of blanching caused by dillucortolone valerate has previously been demonstrated [5] .
In the case of the creams, no statistically significant differences were noted between Nerisone and Temetex in either application mode. Both of these preparations and Synalar cream show statistical equivalence until about 13 h after application in both the occluded and unoccluded modes. From 13to 28 h after application Synalar cream shows significant differences over Nerisone and Temetex creams. No significant differences were observed between Nerisone ointment and cream in the occluded mode. In the unoccluded mode of application Nerisone ointment demonstrated a higher degree of blanching when compared to Nerisone cream. This is expected because of the occlusive nature of the ointment base.
AV e data have been reported in a number of ways, the more usual being summed % TPS and Ave percent x time. Frequently, the terminal reading is taken before the response has reached zero hence only a relative or uncorrected AVe value can be calculated [2] . In order to overcome this a correction factor may be defined as follows:
where (ep)~h is the response at the last sampling time and Ke the elimination rate constant determined from the terminal portion of a semi-log plot of response vs. time [4] . AVe values obtained from the blanching profiles are analogous with blood concentration vs. time curves for oral and parenteral preparations and are therefore of use in defining the bioavailability of the preparations studied [1] .
The difference in the bioavailability relationship between the corrected and uncorrected Ave values should not be so marked if the same steroid is used in the same type of formulation. If however different steroids are used, then large differences in the bioavailability will be observed when using corrected Ave values as opposed to uncorrected values. This is due to the differences in the pharmacokinetic nature of the various synthetic corticosteroids. Pharmacokinetic differences will also be observed between different formulations of the same corticosteroid.
From table I when the corrected and uncorrected AVe values are compared it can be seen that fluocinolone acetonide has a longer duration of action than diflucortolone valerate. This is more marked in the ointments than in the creams. The table also emphasises that there is little difference between the same formulations of diflucortolone valerate prepared by different manufacturers. 
